Tomasz Lawniczek

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Alì Taher, John B. Porter, Vip Viprakasit et al. · Blood · 2012 · 143 citations · Full text

Medicine, Hematology, Pharmacology +16

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Dudley J. Pennell, John B. Porter, Antonio Piga et al. · Blood · 2014 · 120 citations · Full text

Medicine, Hematology, Pharmacology +12

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

Alì Taher, John B. Porter, Vip Viprakasit et al. · Annals of Hematology · 2013 · 72 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

Charalambos Andreadis, Constantine S. Tam, Peter Borchmann et al. · Blood · 2019 · 23 citations

Medicine, Hematology, Oncology +14

Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients

Alì Taher, John B. Porter, Vip Viprakasit et al. · American Journal of Hematology · 2013 · 18 citations · Full text

Medicine, Hematology, Pharmacology +17